Journal article
A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer
Abstract
BACKGROUND: Bone-targeting agents (BTAs), such as bisphosphonates and denosumab, have demonstrated no discernable effects on tumour response or disease free/overall survival in patients with bone metastases from breast cancer. Doxycycline is both osteotropic and has anti-cancer effects. When combined with zoledronate in animal models, doxycycline showed significantly increased inhibition of tumour burden and increased bone formation. We …
Authors
Addison CL; Simos D; Wang Z; Pond G; Smith S; Robertson S; Mazzarello S; Singh G; Vandermeer L; Fernandes R
Journal
Journal of Bone Oncology, Vol. 5, No. 4, pp. 173–179
Publisher
Elsevier
Publication Date
November 2016
DOI
10.1016/j.jbo.2016.06.003
ISSN
2212-1366